An NMDA open-channel blocker (Ki = 1.2 μM at -60 mV) and uncompetitive antagonist with known anti-Parkinsonian, anti-epileptic, anti-stroke, and anti-Alzheimer’s disease properties; 12 μM blocks 90% of NMDA receptor activity and prevents NMDA-receptor mediated neurotoxicity in rat…

A thiazide-like diuretic that targets the Na+-Cl- cotransporter responsible for salt reabsorption in the distal convoluted tubule of the kidney (IC₅₀ = 0.3 µM in rat); inhibits human carbonic anhydrase isoforms VII, XII, and XIII (Kis = 2.1, 5.4, and 15 nM, respectively).

A prodrug that is rapidly catabolized in vivo to 5-fluorouracil when administered by rapid injection; inhibits thymidylate synthase (EC₅₀ = 0.6 nM), interfering with DNA synthesis; used to treat various cancers, particularly metastases to the liver.

A DNA alkylating agents that induces DNA interstrand and intrastrand crosslinks, cytotoxicity, and apoptosis; inhibits the growth of PC-3 prostate cancer cells with IC₅₀ values of 0.074 or 0.77 μM for sequential dosing or single dosing, respectively.

A plant growth regulator involved in the signaling mechanisms for a variety of conditions including plant defense, wound healing, tuberization, fruit ripening, and senescence.

Docosatrienoic acid is a rare ω-3 fatty acid not readily detected in normal phospholipid PUFA pools. It inhibits [3H]-LTB4 binding to pig neutrophils at a concentration of 5 µM.

A potent PR and GR antagonist with Ki value of approximately 1 nM.

5-Bromotetralone is a synthetic intermediate useful for pharmaceutical synthesis.

A progesterone analog (i.e., a progestin); does not bind the ER, however, two of its A-ring metabolites can bind ER and possess weak estrogenic activity.

A receptor antagonist acting at the muscarinic receptors (Ki = 5.5, 47, 0.84, 8.6, and 2.3 nM for M1 through M5, respectively); effective in treating problems related to the lower urinary tract.

2-(hydroxymethyl)-Pyrimidine is a synthetic intermediate useful for pharmaceutical synthesis.

Molecular Formula: C₅₇H₉₂O₆ Formula Weight: 873.4

A selective, endogenous TRPV1 agonist that is a “hybrid” analog, which incorporates components of both the AEA-like and dopamine neurotransmitter pathways; binds to the human recombinant TRPV1 (Ki = 36 nM) with equipotency to that of capsaicin and slightly more potency than that of…

A compound used to attach biotin to primary amines, such as lysines on the surface of proteins, under alkaline conditions (pH~8-9).

An α-hydroxy acid, overproduced in 2-hydroxyglutaric aciduria; mutations in IDH1 and IDH2 cause these enzymes to convert isocitrate to 2-hydroxyglutarate; competitively inhibits α-ketoglutarate-dependent dioxygenases, including lysine demethylases and DNA hydroxylases.

A fluorescent indicator of peroxynitrite formation; neither NO, superoxide, nor hydrogen peroxide alone appear to oxidize DCFH.

The Fatty Acid ethyl ester Standard pack contains a series of nine fatty acid ethyl esters. Each pack contains 100 mg of the ethyl esters of the following fatty acids: stearic, myristic, linoleic, linolenic, arachidonic, oleic, palmitic, lauric, and palmitoleic.

A substrate for the synthesis of RNA during the transcription process and the synthesis of DNA during DNA replication; participates in G-protein-related signal transduction where it is converted to GDP through the action of GTPases.

7-Piperazin-1-yl-thieno[2,3-c] pyridine (hydrochloride) is a synthetic intermediate useful for pharmaceutical synthesis.

An intermediate in the interconversion of glucose and galactose.

An inhibitor of topoisomerase I that demonstrates less toxicity than its parent compound; demonstrates strong anti-tumor activity against a wide range of experimental tumors including L1210 leukemia cells (IC₅₀ = 1.15 μM).

FeTMPyP is a synthetic porphyrin complexed with iron, which acts as a peroxynitrite decomposition catalyst. The rate constant for decomposition of peroxynitrite by FeTMPyP is 2.2 x 106 M−1s−1 with a turnover number of 360 ± 170 s−1. The predominant product (>90%) of this…

A synthetic intermediate used in glycosylation reactions.

A cell permeable, competitive inhibitor of HIF-PH with effective concentrations in the low µM range.

A cell permeable derivative of GSH that undergoes hydrolysis by intracellular esterases to release GSH; used to protect cells against damage from radiation, oxidants, and various toxic compounds including heavy metals.

A synthetic cytokinin used as a media supplement to regulate growth in woody plant tissue cultures and micropropagations; concentrations below 1 µM promote axillary proliferation, whereas concentrations above 1 µM can stimulate the formation of callus, adventitious shoots, or somatic embryos.

An agonist of dopamine D1A (D1R) and D1B (D5R) receptors (Kds = 17 and 11 nM, respectively); alters hemodynamic properties, including hypertension, in animals.

A skeletal muscle relaxant that has applications in reducing muscle spasm, limitations in normal motion, and pain caused by musculoskeletal conditions.

A potent dopamine receptor agonist that binds the D2 receptor with highest affinity (Ki = 2.5 nM); avidly binds the serotonin receptors 5-HT1A and 5-HT1D (Ki = 12.9 and 10.7 nM, respectively), as well as α and β adrenoreceptors.

A competitive HDAC inhibitor that inhibits HDAC1 (IC50 = 0.25 μM) and HDAC3 (IC50 = 0.30 μM); causes cell differentiation, cell cycle arrest, or apoptosis.

An atypical antidepressant with diverse actions, most notably on the glutamatergic system; attenuates glutamate release and modulates the function of AMPAR; acts as an agonist of the µ-opioid receptor (EC₅₀s = 194 and 641 nM for human and mouse receptors, respectively).

A prodrug that is metabolized in vivo to RNH-6270, a nonpeptide angiotensin II antagonist that potently inhibits angiotensin binding to the AT1 receptor (IC50 = 7.7 nM) without affecting binding to the AT2 receptor; reduces blood pressure.